Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

phenol oropharyngeal (Cepastat, Ulcerease, Chloraseptic, Chloraseptic Warming Sore Throat Spray): Dosing and Uses

 

Classes: Local Anesthetics, Dental

Medically reviewed by Min Clinic Staff | Updated: January 2026

Dosing and uses of Cepastat, Ulcerease (phenol oropharyngeal)

 

Adult dosage forms and strengths

oral solution (mouthwash/gargle)

  • 0.6% (Ulcerease)

oral solution (spray)

  • 1.4% (Chloraseptic)

lozenge (oral)

  • 14.5mg (Cepastat)

 

Sore Throat

Ulcerease: Gargle or swish for 15 seconds, then expectorate; may repeat q2h

Chloraseptic: 5 sprays onto throat or affected area; may repeat q2h

Cepastat: Use up to 2 lozenges q2h PRn

 

Antiseptic Topical

Apply sparse amount gently to affected area once or q8-12hr

 

Pediatric dosage forms and strengths

oral solution (mouthwash/gargle)

  • 0.6% (Ulcerease)

oral solution (spray)

  • 1.4% (Chloraseptic)

lozenge (oral)

  • 14.5mg (Cepastat)

 

Sore Throat

Ulcerease

  • <3 years: Not established
  • >3 years: Administer as in adults

Chloraseptic

  • <2 years: Not established
  • 2-12 years: 3 sprays onto throat or affected areas; may repeat q2h
  • >12 years: Administer as in adults

Cepastat

  • <6 years: Not established
  • 6-12 years: 1 lozenge q2h PRN; not to exceed 10 lozenges/24 hours
  • >12 years: Administer as in adults

 

Cepastat, Ulcerease (phenol oropharyngeal) adverse (side) effects

Frequency Not Specified

Acute epiglotitis

Edema of the epiglotitis/larynx

 

Warnings

Contraindications

Documented hypersensitivity

 

Cautions

Overdose may cause agitation, confusion, slurred speech, and CNS depression

Do not use for sore >7 days if pain, redness, or irritation continues

 

Pregnancy and lactation

Pregnancy category: C

 

Pregnancy categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

 

Pharmacology of Cepastat, Ulcerease (phenol oropharyngeal)

Mechanism of action

Disinfectant, antiseptic, and local anesthetic

 

Pharmacokinetics

Metabolism: Metabolized to phenylglucuronide and phnyl sulfate, small amounts oxidized to catechol and quinoL

Excretion: Via urine